Inhibition of adenovirus transport from the endosome to the cell nucleus by rotenone.
adenovirus infection
antiviral compound
cytomegalovirus
microtubular polymerization
rotenoids
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
09
2023
accepted:
27
12
2023
medline:
26
1
2024
pubmed:
26
1
2024
entrez:
26
1
2024
Statut:
epublish
Résumé
Regardless of the clinical impact of human adenovirus (HAdV) infections in the healthy population and its high morbidity in immunosuppressed patients, a specific treatment is still not yet available. In this study, we screened the CM1407 COST Action's chemical library, comprising 1,233 natural products to identify compounds that restrict HAdV infection. Among them, we identified rotenolone, a compound that significantly inhibited HAdV infection. Next, we selected four isoflavonoid-type compounds (e.g., rotenone, deguelin, millettone, and tephrosin), namely rotenoids, structurally related to rotenolone in order to evaluate and characterized
Identifiants
pubmed: 38273842
doi: 10.3389/fphar.2023.1293296
pii: 1293296
pmc: PMC10808720
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1293296Informations de copyright
Copyright © 2024 Balsera-Manzanero, Ghirga, Ruiz-Molina, Mori, Pachón, Botta, Cordero, Quaglio and Sánchez-Céspedes.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.